Literature DB >> 21398070

Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.

Nan-Yao Lee1, Wei-Han Huang, Ko-Chung Tsui, Po-Ren Hsueh, Wen-Chien Ko.   

Abstract

For 244 patients with bacteremia due to extended-spectrum β-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae treated by ertapenem (73, 29.9%) or either imipenem or meropenem (171, 70.1%), the therapeutic efficacy was evaluated. Ertapenem therapy was effective for patients with ESBL-producing E. coli or K. pneumoniae bacteremia in terms of mortality and microbiological responses, as compared with imipenem or meropenem.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21398070     DOI： 10.1016/j.diagmicrobio.2010.12.008

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  11 in total

1.  Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.

Authors:  Belén Gutiérrez-Gutiérrez; Robert A Bonomo; Yehuda Carmeli; David L Paterson; Benito Almirante; Luis Martínez-Martínez; Antonio Oliver; Esther Calbo; Carmen Peña; Murat Akova; Johann Pitout; Julia Origüen; Vicente Pintado; Elisa García-Vázquez; Oriol Gasch; Axel Hamprecht; Nuria Prim; Mario Tumbarello; German Bou; Pierluigi Viale; Evelina Tacconelli; Manel Almela; Federico Pérez; Helen Giamarellou; José Miguel Cisneros; Mitchell J Schwaber; Mario Venditti; Warren Lowman; Joaquín Bermejo; Po-Ren Hsueh; Marta Mora-Rillo; Irene Gracia-Ahulfinger; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  J Antimicrob Chemother       Date:  2016-02-22       Impact factor: 5.790

Review 2.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

3.  Thirty-Day Mortality Rates in Patients with Extended-Spectrum β-Lactamase-Producing Enterobacterales Bacteremia Receiving Ertapenem versus Other Carbapenems.

Authors:  Jin Ju Park; Eun-Ju Jung; Jae-Young Kim; Yu Bin Seo; Jacob Lee; Younghee Jung
Journal:  Antimicrob Agents Chemother       Date:  2022-06-16       Impact factor: 5.938

4.  Susceptibility of Selected Multi-Drug Resistant Clinical Isolates to Leaves of Carpolobia lutea.

Authors:  Ibikunle Anibijuwon; Ifeoluwa Gbala; Jumai Abioye
Journal:  Ethiop J Health Sci       Date:  2018-03

5.  Potentials of Actinomycetes from Reserved Environments as Antibacterial Agents Against Drug-Resistant Clinical Bacterial Strains.

Authors:  Risikat Nike Ahmed; Folake Daniel; Ifeoluwa Deborah Gbala; Alhassan Sanni
Journal:  Ethiop J Health Sci       Date:  2020-03

Review 6.  Strategies to minimize antibiotic resistance.

Authors:  Chang-Ro Lee; Ill Hwan Cho; Byeong Chul Jeong; Sang Hee Lee
Journal:  Int J Environ Res Public Health       Date:  2013-09-12       Impact factor: 3.390

7.  Clinical Efficacy of Ertapenem for Recurrent Cystitis Caused by Multidrug-Resistant Extended-Spectrum β-Lactamase-Producing Escherichia coli in Female Outpatients.

Authors:  Sungmin Song; Chulsung Kim; Donghoon Lim
Journal:  Korean J Urol       Date:  2014-04-10

8.  Evaluation of Ertapenem use with impact assessment on extended-spectrum beta-lactamases (ESBL) production and gram-negative resistance in Singapore General Hospital (SGH).

Authors:  Cheryl Li-Ling Lim; Winnie Lee; Amanda Ling-Chiu Lee; Lisa Ting-Ting Liew; Szu Chin Nah; Choon Nam Wan; Maciej Piotr Chlebicki; Andrea Lay-Hoon Kwa
Journal:  BMC Infect Dis       Date:  2013-11-06       Impact factor: 3.090

9.  Effects of Group 1 versus Group 2 carbapenems on the susceptibility of Acinetobacter baumannii to carbapenems: a before and after intervention study of carbapenem-use stewardship.

Authors:  Young Kyung Yoon; Kyung Sook Yang; Seung Eun Lee; Hyun Jeong Kim; Jang Wook Sohn; Min Ja Kim
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

10.  Outcomes and Risk Factors for Mortality among Patients Treated with Carbapenems for Klebsiella spp. Bacteremia.

Authors:  Lauren R Biehle; Jessica M Cottreau; David J Thompson; Rachel L Filipek; J Nicholas O'Donnell; Todd M Lasco; Monica V Mahoney; Elizabeth B Hirsch
Journal:  PLoS One       Date:  2015-11-30       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.